The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury

Lucía Barbier-Torres1, Paula Iruzubieta1,2, David Fernández-Ramos1

  • 1Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park, Derio, 48160, Bizkaia, Spain.

Nature Communications
|December 14, 2017
PubMed

Insights

Acetaminophen (APAP) overdose causes liver injury by disrupting mitochondrial function via MCJ. Inhibiting MCJ protects the liver, offering a potential new therapy for APAP-induced liver damage.

Area of Science:

  • Hepatology
  • Mitochondrial Biology
  • Toxicology

Background:

  • Acetaminophen (APAP) overdose is a leading cause of acute liver failure worldwide.
  • Mitochondrial dysfunction is implicated in APAP-induced liver injury, but mechanisms remain unclear.
  • Current therapies like N-acetylcysteine are not always effective.

Purpose of the Study:

  • To elucidate the mechanism of APAP-induced hepatotoxicity.
  • To identify novel therapeutic targets for APAP-induced liver injury.
  • To evaluate the role of mitochondrial protein MCJ in APAP toxicity.

Main Methods:

  • Investigated APAP's effect on mitochondrial respiratory supercomplexes in vitro and in vivo.
  • Utilized MCJ inhibitors in animal models of APAP overdose.
  • Analyzed MCJ levels in liver samples from patients with acetaminophen overdose.

Main Results:

  • APAP disrupts mitochondrial respiratory supercomplex formation by interacting with MCJ.
  • This disruption leads to reduced ATP production and increased reactive oxygen species (ROS) generation.
  • Inhibition of MCJ protected against APAP-induced liver injury, outperforming N-acetylcysteine.
  • Elevated MCJ levels were observed in human acetaminophen overdose cases.

Conclusions:

  • MCJ plays a critical role in APAP-induced hepatotoxicity.
  • Targeting MCJ represents a promising therapeutic strategy for acetaminophen overdose.
  • MCJ inhibition offers a potential alternative or adjunct therapy for liver injury prevention and treatment.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.1K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
12
Mitochondrial Membranes01:45

Mitochondrial Membranes

A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.4K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212